2021 Predictions: a BioCentury survey
BioCentury’s SAB weighs in on what to expect in biotech in 2021 (See link at end to participate)
BioCentury’s SAB weighs in on what to expect in biotech in 2021. (Click link at end to add your predictions)
While the pandemic has put much of normal life on hold, the biotech industry has continued to hum along, funding and advancing R&D while simultaneously ushering the world into the post-COVID era one vaccination at a time.
BioCentury surveyed members of its scientific advisory board and select other KOLs from December 2 to 8 about their expectations for innovation, clinical readouts, COVID-19 and the financing and dealmaking landscape in 2021. The respondents were a cohort of 18 biopharma C-suite executives, pharma R&D heads and investors based in the U.S., Europe and China. Responses were anonymous.
Two findings stand out: overwhelming confidence that mRNA technology will take off, and a strong expectation for more consolidation among the mega-cap biopharmas. In addition, the needle might start to move for greater representation of racial and ethnic minorities in clinical trials.
If the group’s predictions hold true, the new year could also see a continuation of 2020’s IPO boom and some new targets and technologies show clinical proof of concept, but bring disappointments on the Alzheimer’s front.
Translational science: what’s hot and what’s not
Almost all the respondents think it is unlikely that 2021 will yield clinical proof of concept for a tau-targeting Alzheimer’s disease candidate. Two